Gerard Sanacora

Oct 14, 2024 | nature.com | Todd Lencz |Brian J Mickey |James W Murrough |Sean M. Nestor |Thomas Nickl-Jockschat |Sina Nikayin | +6 more

AbstractGenome-wide association studies (GWASs) of major depressive disorder (MDD) have recently achieved extremely large sample sizes and yielded substantial numbers of genome-wide significant loci. Because of the approach to ascertainment and assessment in many of these studies, some of these loci appear to be associated with dysphoria rather than with MDD, potentially decreasing the clinical relevance of the findings.

Jan 3, 2024 | jamanetwork.com | Samuel T. Wilkinson |Joseph Palamar |Gerard Sanacora

The Rapidly Shifting Ketamine Landscape in the US In recent years, ketamine has been hailed as a miracle treatment for depression and related disorders. The US Food and Drug Administration (FDA) approved the S-enantiomer of ketamine, esketamine, as the first antidepressant in a new class for treatment-resistant depression in 2019.1 Emerging evidence suggests that the landscape of ketamine both as a medical therapeutic and as a recreational substance is shifting.

Dec 6, 2023 | psychiatrictimes.com | Gerard Sanacora

CONFERENCE REPORTERGerard Sanacora, MD, PhD, sat down with Psychiatric Times at the American College of Neuropsychopharmacology 2023 Annual Meeting to discuss the session he chaired, "Larger Scale Data Informing the Use of ECT and Ketamine/Esketamine in Severe and Treatment Resistant Major Depressive Disorder."The reviewed studies at this session are "some of the biggest we are ever going to see," and will help guide clinical practice. Dr Sanacora is George D. Gross and Esther S.

Oct 19, 2023 | nature.com | Gerard Sanacora

Numerous randomized placebo-controlled studies over the past two decades have shown that ketamine has a rapid antidepressant action. However, its acute transient effects on cognition and perception are likely to unmask study-arm assignment. Now, the use of surgical anesthesia to conceal treatment assignment finds high rates of rapid antidepressant response among participants, regardless of whether they are randomized to ketamine or placebo.

May 12, 2023 | nature.com | Gerard Sanacora

AbstractPatients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatment choices with sustained efficacy and long-term tolerability.